Research Papers:
Involvement of calprotectin (S100A8/A9) in molecular pathways associated with HNSCC
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2295 views | HTML 3768 views | ?
Abstract
Ali Khammanivong1,4,5, Brent S. Sorenson1, Karen F. Ross1,2, Erin B. Dickerson4,5, Rifat Hasina3, Mark W. Lingen3 and Mark C. Herzberg1,2
1 Department of Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, USA
2 Mucosal and Vaccine Research Center, Minneapolis VA Medical Center, Minneapolis, MN, USA
3 Department of Pathology, University of Chicago, Chicago, IL, USA
4 Department of Veterinary Clinical Sciences, University of Minnesota, St. Paul, MN, USA
5 Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA
Correspondence to:
Mark C. Herzberg, email:
Keywords: calprotectin, S100A8/A9, cell cycle, differentiation, carcinogenesis
Received: November 04, 2015 Accepted: January 29, 2016 Published: February 13, 2016
Abstract
Calprotectin (S100A8/A9), a heterodimeric protein complex of calcium-binding proteins S100A8 and S100A9, plays key roles in cell cycle regulation and inflammation, with potential functions in squamous cell differentiation. While upregulated in many cancers, S100A8/A9 is downregulated in squamous cell carcinomas of the cervix, esophagus, and the head and neck (HNSCC). We previously reported that ectopic S100A8/A9 expression inhibits cell cycle progression in carcinoma cells. Here, we show that declining expression of S100A8/A9 in patients with HNSCC is associated with increased DNA methylation, less differentiated tumors, and reduced overall survival. Upon ectopic over-expression of S100A8/A9, the cancer phenotype of S100A8/A9-negative carcinoma cells was suppressed in vitro and tumor growth in vivo was significantly decreased. MMP1, INHBA, FST, LAMC2, CCL3, SULF1, and SLC16A1 were significantly upregulated in HNSCC but were downregulated by S100A8/A9 expression. Our findings strongly suggest that downregulation of S100A8/A9 through epigenetic mechanisms may contribute to increased proliferation, malignant transformation, and disease progression in HNSCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7373